MicroRNA 448 (miR-448)

MicroRNA 448 (miR-448) is a small, endogenous, non-coding RNA molecule, approximately 22 nucleotides in length, involved in the post-transcriptional regulation of gene expression by binding to complementary sequences in the 3′ untranslated regions of target mRNAs, resulting in translational repression or mRNA degradation. It has been shown to play key roles in cell proliferation, differentiation, apoptosis, and the epithelial-mesenchymal transition, and is implicated in the development and progression of multiple malignancies, including lung, colon, breast, and liver cancers[1][2][3][4]. miR-448 also participates in metabolic regulation (adipocyte differentiation), immune responses (such as blocking hepatitis C virus replication), and nervous system pathology (response to neurotoxins). Its dysregulation is associated with cancer biology, neurodegenerative states, and obesity, and it is being explored as both a biomarker and a potential therapeutic target, although no clinically approved drugs directly targeting miR-448 currently exist.

Other names

hsa-mir-448MIRN448hsa-miR-448miRNA448MIR448

Antisense oligonucleotide-mediated inhibition or mimic-mediated overexpression (investigational, for altering miR-448 activity in laboratory models; not yet clinical drugs) Downregulation of target oncogenes such as IRS2, SIRT1, E2F3, KLF5 leading to inhibition of cell proliferation, migration, and EMT in cancer Inhibition of hepatitis C virus replication (potential mechanism in infection)